Kisspeptin Side Effects: A Research Hormone, Not an Approved Therapeutic
Kisspeptin is a hypothalamic neuropeptide that stimulates GnRH and downstream release of LH and FSH. It is studied in clinical research for reproductive disorders, including hypothalamic amenorrhea and hypogonadism, but it is not an FDA-, EMA-, or TGA-approved therapeutic. Marketed online for fertility or hormone support, those uses are not regulator-endorsed.
Kisspeptin is approved in some jurisdictions but not in others. Investigational. Studied in academic clinical trials for reproductive disorders. Not approved by the FDA, EMA, or TGA. This page summarises the published literature and regulator positions. It is not medical advice.
Key Takeaways
- Kisspeptin is a research hormone, not an approved therapeutic.
- Studied in academic clinical trials for hypothalamic amenorrhea, hypogonadism, and IVF triggering.
- Not FDA-, EMA-, or TGA-approved.
- Stimulates LH, FSH, and gonadal steroid release, which may affect menstrual cycle, fertility, and mood.
- Interactions with hormonal contraceptives, HRT, and fertility treatments are not characterised in regulator-reviewed datasets.
What is Kisspeptin, and what is it marketed for?
Kisspeptin (KISS1-derived peptide). Kisspeptin signals through the KISS1R (GPR54) receptor to stimulate gonadotropin-releasing hormone (GnRH) secretion. Subsequent LH and FSH release drive gonadal steroid production. Research groups including those of Dhillo and colleagues at Imperial College London have studied kisspeptin in hypothalamic amenorrhea, hypogonadism, IVF triggering, and emotional regulation.
What side effects and safety concerns have been reported?
The summary below draws from the published literature and regulator statements. Severity classification follows the source documents.
| Concern | What has been reported | Source |
|---|---|---|
| Hormonal effects | Kisspeptin stimulates LH, FSH, and gonadal steroid release | Mechanism may affect menstrual cycle, fertility, and mood |
| Long-term safety | Not characterised outside short clinical trials | Most published trials are short-duration |
| Drug interactions | Interactions with hormonal contraceptives, HRT, and fertility medicines are not characterised in regulator datasets | No labelled interactions |
| Injection infection (compounded) | Pain, abscess, sepsis from non-sterile product | Compounded peptide quality is variable |
Taking Kisspeptin alongside prescription medicines?
Allmeds scans interactions across your full medication list. Free for individuals.
Common Questions About Kisspeptin
No. Kisspeptin is investigational. It is studied in academic clinical trials but is not approved by the FDA, EMA, or TGA as a therapeutic.
Kisspeptin stimulates GnRH and downstream LH and FSH release. Research groups have studied it in hypothalamic amenorrhea, hypogonadism, IVF triggering, and emotional regulation. The data are interesting but limited to clinical-research contexts.
Because kisspeptin stimulates reproductive hormones, it has the potential to affect menstrual cycle, fertility, and mood. Use outside a supervised clinical trial is not appropriate. Discuss any concerns with a reproductive endocrinologist.
Interactions with hormonal contraceptives, HRT, and fertility medicines are not characterised in regulator-reviewed datasets. Do not combine without specialist advice.
References
- Jayasena CN, Dhillo WS. Kisspeptin offers a new tool to study reproductive endocrinology. Eur J Endocrinol. 2014. Source.
- Abbara A et al. Kisspeptin: a novel hormone for assisted reproduction. Hum Reprod Update. 2014. Source.
- U.S. Food & Drug Administration. FDA position on bulk drug substances for compounding. Source.